Original Article

Construction of a Recombinant Bacmid DNA to Express Influenza Virus Matrix Protein1 (M1) in Insect Cell Line

Salmani Z¹, Behzadian F¹*, Fotouhi-Chahooki F², Fallah J¹

1. Molecular Genetics Dept, Research center for Sciences and Biotechnology, Tehran, Iran.

2. Influenza group, Pasteur Institute, Tehran, Iran.

Abstract

Background and Aims: Virus-like particles (VLPs) have been suggested to be a promising recombinant vaccine approach. Several studies have reported that the influenza VLPs produced in insect cells is an effective vaccine candidate. Due to crucial role of matrix M1 protein in assembly and budding of Influenza particles, in all VLPs structures, M1 protein have been considered as a main component.

Methods: M1 open reading frame (759 bp) from human influenza virus A /New Caledonia 20/1999/ (H1N1) was amplified by RT-PCR. The amplicone was cloned into pFastBac1 donor plasmid through KpnI/XhoI sites. After verification of clone by restriction analysis, it was subjected to automated sequencing. The M1 recombinant bacmid was subsequently generated and verified by PCR using M1 specific and M13 universal primers.

Results: results showed that a recombinant baculovirus containing correct and inframe sequence of Influenza M1 gene under control of polyhedrin promoter has been constructed.

Conclusion: The above-mentioned M1 recombinant baculovirus can be used with other individual recombinant baculoviruses expressing HA and NA genes to produce influenza VLPs in insect cell line.

Keywords: M1 protein; Influenza; Virus-like particles (VLPs)

Introduction

Influenza A viruses, members of Ortomyxoviridae family, are able to infect a large variety of animals as well as humans. Influenza A viruses with segmentednegative strand genome are classified based on the antigenic properties of their two distinct surface glycoproteins, haemagglutinin (HA) and neuraminidase (NA) which are located on the outer host-cell-derived envelope. The Matrix protein (M2), a nonglycosylated integral membrane protein presents in outer membrane that acts as an ionic channel. The Matrix protein (M1) which is lined within the outer envelope interacting with the ribonucleoprotein (RNP) and plays an essential role in virion assembly, budding and release (1, 2).

Studies have shown that mutations on M1 and M2 genes, both encoded from segment 7, lead to changes in the morphology of the wild-type virion. These observations indicate the crucial role of these two proteins in virion structure (3).

Moreover, research on Influenza virus-like particle (VLP) formation clearly demonstrates the significant role of the M1 protein beside of the other structural components in assembly, formation and budding process, although it is driven by a single expression of the M1 protein

^{*}Corresponding author: Farida Behzadian, Ph.D, Department of Molecular Genetics, Research Center for Sciences and Biotechnology, Lavizan, Tehran, Iran. PO: 15875-1774 Email: fbehzadian@yahoo.com

(4). It has been shown that even VLPs lacking either HA or NA could be formed and released from the cell expressing M1 from recombinant DNA or virus infected cell (5, 6).

The recombinant baculovirus and insect cell expression system provides high levels of recombinant protein that undergoes posttranslational modification like glycosylation (7, 8). Therefore, application of such system allows large quantity production of a desirable protein, in native configuration as a vaccine.

In this study M1 gene was isolated and amplified from H1N1 influenza virus and then a clone of M1 recombinant bacmid was constructed. This construct can be used to produce VLPs of different influenza genotypes because M1 sequences have remained evolutionarily stable for all recorded human and avian influenza A viruses during the past decades (9). M1 recombinant bacmid also can be used to produce large scale of M1 protein, suitable for vaccine production.

Methods

RNA Extraction and cDNA synthesis

The human influenza virus A /New Caledonia 20/1999/ (H1N1) was propagated and harvested in MDCK cells according to the standard protocols (10). Viral RNA was extracted from 200 µl of harvested cell culture supernatant using a commercial RNX-PLUSTM solution (Cinnagen-Iran). The viral RNA was eluted in 30 µl DEPC-treated water. The synthesis performed cDNA was using RevertAid First Strand cDNA Synthesis Kit (Fermantas-Lithuania) according to manufacturer's instructions. The primer Uni12 5'-AGCRAAAGCAGG-3', which is complementary to the conserved 3'end of all influenza A virus RNA segments was used for cDNA synthesis (11).

RT-PCR

A set of forward and reverse primers were designed by Gene Runner 3.05 (Hastings software, Inc) to amplify the complete M1 ORF of H1N1 Influenza virus (759bp). 5µl of cDNA was added to a total 20µl of PCR mixture containing 20pmol of each forward primer 5'AGCTCGAGATGAGTCTTCTAAC CGA 3' and reverse primer 5'ACTGGTACCT CAC-TTGAATCGTTGCA 3' (underlined nucleotides correspond to XhoI and KpnI sites respectively), 10 mM Tris-Cl pH 8.3, 50 mM KCl, 1.5 mM MgCl₂, 10 mM dNTPs, High Fidelity PCR Enzyme Mix (Fermentas-Lithuania) and covered with 50 µl of mineral oil. Amplification reactions were performed in a thermocycler (Master Cycler, Eppendorf) under the following profile: 3 min at 95°C followed by 30 cycles at 95°C for 1 min, 55°C for 1 min and 72°C for 1 min, with a final extension step at 72°C for 10 min. PCR products were analyzed on 1% (w/v) agarose gel electrophoresis stained with ethidium bromide upon preparation (12, 13).

Cloning of the M1 gene

The RT-PCR product was extracted and cleaned up from the agarose gel using DNA extraction kit (Bioneer-Korea) and subsequently cloned into the KpnI and XhoI sites of the pFastBac1 donor plasmid (Invitrogen-USA). The recombinant vector pFastBacM1 was confirmed using restriction analysis. Subsequently enzyme it was subjected automatic onedirected to sequencing using forward primer as described previously for M1 amplification.

Generation of recombinant bacmid

The recombinant donor plasmid, pFastBacM1, was transferred into the E.coli DH10Bac competent cells for site-specific transposition of the M1 DNA from the transposing vector to a bacmid DNA through lacZ gene disruption. The transformed cells were plated onto the LB kanamycin agar containing $(50\mu g/ml)$, gentamicin (7µg/ml), tetracycline (10µg/ml), X-gal $(100 \mu g/ml)$ and isopropylthio-βgalactoside (IPTG, 40µg/ml) and incubated at 37°C for 48h. The high-molecular-weight bacmid DNA was isolated from the overnight cultures by alkaline lysis purification according instructions supplied to the by the

manufacturer (Invitrogen-USA). Successful transposition was verified by PCR analysis using either M13/pUC or M1-specific primers.

Results

Amplification and characterization of the M1 gene

The full length sequence of M1 gene (759bp) was amplified by RT-PCR using the designed specific primers (Fig 1). The fidelity of the M1 open reading frame (ORF) in pFastBacM1 was confirmed by sequencing. Analysis of sequencing was accomplished by Chromas software (version 1.45 - Australia).

Construction of the recombinant bacmid DNA

The M1 gene was cloned into pFastBac1 plasmid and verified by restriction endonuclease digestion in comparison with pFastBac1, as control (Fig 2). Following the transformation and plating of the cells on LB agar, the transposed colonies were visible as large white colonies among the blue ones harboring the unaltered bacmid. The selected white colonies were restreaked onto LB agar plate to ensure if they have true white phenotype.



Fig. 1. Gel electrophoresis of M1 gene RT-PCR products, Lane 1: demonstrating thick bond of 759bp amplicone run along with molecular weight DNA marker Lane 2: negative control (blank).



Fig. 2. Pattern of restriction enzymes digestion confirming new recombinant pFastBacM1. HindIII/XhoI double digestion on pFastBacM1(clone) revealed expected 304bp, 457bp and 4862bp fragments (lane1). Single digestion of KpnI and XhoI made the construct linear and released 5639bp bands (lane 2 and 3). BamHI digestion also generated expected 359bp, 5280bp fragments (lane 4). Whereas, all such digestions made pFastBac (nonclone) linear with 4775bp in length (lanes 1-4 on right panel). 100bp and 1Kb molecular weight DNA marker (Fermentas) applied as scale.

Since verification of the high-molecular weight recombinant bacmid DNA by digestion is not convenient, PCR was performed using M13/pUC and M1-specific primers to ensure proper transposition of the target gene in the recombinant bacmid. The bacmid DNA contains M13 forward and reverse priming sites flanking the mini-att Tn7 site within the LacZ α -complementation region. A panel of PCR reactions was done using M1 specific primers, M13/pUC primers, M1 gene specific forward and M13 reverse primers, and M1 gene specific reverse and M13 forward primers for 759bp, 3059bp, 2074bp, 2725bp PCR products respectively. Amplification of the nonrecombinant bacmid using M13/pUC primers generated a 303bp band (Fig 3).



Fig. 3. A panel of PCR done to confirm M1 recombinant Bacmid

Lane 1, 100 bp molecular weight DNA marker (Fermentas).

Lane 2, PCR product using M1 specific primers on recombinant bacmid extracted from white colony (759bp).

Lane 3, PCR product using M13 specific primers (303bp) on nonrecombinant bacmid extracted from blue colony as a negative control.

Lane 4, PCR product using M1 forward and M13 reverse primers (~1400bp) on recombinant bacmid extracted from white colony.

Lane 5, PCR product using M13 specific primers (3059bp) on recombinant bacmid extracted from white colony.

Lane 6, PCR product using M13 forward and M1 reverse primers (2507bp) on recombinant bacmid extracted from white colonies.

Lane 7, 1kb molecular weight DNA marker (Fermentas).

Discussion

The expression of eukaryotic genes using baculovirus expression vectors takes advantages of their protein synthesis machinery and facilitates proper folding and post-translational modifications including glycosylation, acetylation, olygomerization and proteolysis. In addition, the insect cell cytoplasmic environment provides appropriate disulfide bridge assembly (14, 15). These features are important in the case of influenza A M1 protein, as its proper structure is critical for its function as a nexus that gather ribonucleoprotein complex and outer envelopebound HA, NA, and M2 proteins together for packaging in host cell (5, 16). Production of Influenza VLP was demonstrated with different expression systems including recombinant DNA expression vectors (17), recombinant vaccinia viruses (16), and DNA plasmid transfection with T7 **RNA** polymerase-expressing vaccinia virus (5). However recombinant baculoviruses/ insect cell expression system yields high levels of recombinant proteins and more important, VLPs have been formed in such systems have been shown highly immunogenic both in neutralizing antibodies and cellular immune responses. Several research groups have reported the expression of the M1 Influenza in baculovirus-infected insect cells. Most of them planned to produce Influenza A virus like particles (VLPs) of different genotypes and apply them in vaccine research studies (18. 19, 20, 21).

Gomez-Puertas and colleagues studies have clearly demonstrated the significance of M1 protein in the assembly and budding process of influenza VLP formation (5, 22). Therefore, in the most influenza VLP studies, M1 protein has been considered as an essential component (18, 19, 20, 21). It is also demonstrated that VLPs lacking either HA or NA have been formed and released from cells expressing M1 through recombinant DNA or virus infection (16). In other word, even expression of M1 protein alone is sufficient to induce particle formation. In this work, a recombinant baculovirus containing correct and inframe sequence of Influenza M1 gene under control of polyhedrin promoter has been constructed. Owing to our ultimate goal to produce H1N1 influenza VLP, we chose the Bac-to-Bac expression system (Invitrogen life technologies) because apart from the above mentioned advantages, it is a valid and multipurpose system for the production of the recombinant proteins.

In ongoing study, the M1 recombinant bacmid constructed here will transfect into the cultured Sf9 (Spodoptera frugiperda) insect cell line to produce recombinant baculovirus expressing M1 gene. Recombinant baculovirus expressing M1 gene can be used with other individual recombinant baculoviruses expressing HA and/or NA genes to produce influenza VLPs. Moreover, the M1 protein expressed in this system after purification is applicable in several vaccine research projects.

References

1. Knipe DM, Howley PM. Field virology. 4th edition. USA: Lippincott Williams & Wilkins; 2001.

2. Nicholson KG, Webster RG, Hay AJ. Textbook of influenza. Blackwell Science Publisher; 1998.

3. Latham T and Galarza JM. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J of Virology 2001; 6154–6165.

4. Jin H, Leser GP, Zhang J and Lamb RA. Influenza virus haemagglutinin and neuraminidase cytoplasmic tails control particle shape. EMBO J 1997; 16: 1236–1247.

5. Go'mez-Puertas P, Albo C, Pe'rez-Pastrana E, Vivo A and Portela A. Influenza virus matrix protein is the major driving force in virus budding. J ViroL 2000; 74: 11538–11547.

6. Kretzschmar E, Bui M and Rose JK. Membrane association of influenza virus matrix protein does not require specific hydrophobic domains or the viral glycoproteins.Virology 220: 1996; 37–45. 7. Anderson D, Harris R, Polayers D, Ciccarone V, Donahue R, Gerald G, Jessee J, Luckow Rapid generation and V. of recombinant baculovirus and expression of using BAC-to-BAC foreign genes the baculovirus expression system. FOCUS 1995; 17(2):53-58.

8. Luckow VA, Lee SC, Barry GF and Olins PO. Efficient generation of infectious recombinant baculoviruses by site-specific transposon-mediated insertion of foreign genes into a baculovirus genome propagated in Escherichia Coli. J Virol 1993; 67(8): 4566-4579.

9. Tan PT, Heiny AT, Miotto O, Salmon J, Ernesto TA, Marques JR, Lemonnier F, and August JT. Conservation and diversity of influenza A H1N1 HLA-restricted T cell epitope candidates for epitope-based vaccines: PLoS ONE 2010; Volume 5: Issue 1, e8754.

10. Burleson GB, Chambers TM, Wiedbrauk DL. Virology: A Laboratory Manual, Academic Press Inc; 1992.

11. Hoffmann E, Stech J, Guan Y, Webster RG and Perez DR. Universal primer set for the full-length amplification of all influenza a viruses. Arch Virol 2001; 146: 2275–2289.

12. Sambrook J, Russell D. Molecular cloning: A Laboratory Manual 3th ed. USA: Cold Spring Harbor; 2001.

13. Ausubel FM, Brent R, Kingston RE. Short Protocols in Molecular Biology. 3th ed. USA: John Willy & Sons; 1995.

14. Li B, Wu HY, Qian XP, Li Y, and Chen WF. Expression, purification and serological analysis of hepatocellular carcinoma associated antigen HCA587 in insect cells. World J Gastroenterol 2003; 9 (4): 678-682.

15. Roy P, Mikhailov M, Bishop D. Baculovirus multigene expression vectors and their use for understanding the assembly process of architecturally complex virus particles. Gene 1997; 190: 119-129.

16. Ali A, Avalos RT, Pomimaskin E and Nayak DP. Influenza virus assembly: effect of influenza virus glycoproteins on the membrane association of M1 protein. J Virol 2000; 74: 8709–8719.

17. Chen BJ, Leser GP, Morit E, and Lamb RA. Influenza virus haemagglutinin and

neuraminidase, but not the matrix protein, are required for assembly and budding of plasmidderived virus-like particles. J Virol 2007; 81(13): 7111–7123.

18. Quan FS, Huang C, Compans RW, and Kang SM. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol 2007; 81 (7): 3514–3524.

19. Wang BZ, Quan FS, Kang SM, Bozja J, Skountzou I, and Compans RW. Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J Virol 2008; 82 (23): 11813–11823.

20. Mahmood K, Bright RA, Mytle N, Carter DM, Crevar CJ, Achenbach JE, Heaton PM,

Tumpey TM, and Ross TM. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 2008; 26 (42): 5393–5399.

21. Kang SM, Yoo DG, Lipatov AS, Song JM, Davis CT, Quan FS, Chen LM, Donis RO, and Compans RW. Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS ONE 2009; 4 (3): e4667.

22. Go'mez-Puertas P, Mena I, Castillo M, Vivo A, Pe'rez Pastrana E and Portela A. Efficient formation of influenza virus-like particles: dependence on the levels of viral proteins. J Gen Virol 1999; 80:1635–1645.